Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
暂无分享,去创建一个
J. Montaner | E. Seminari | J. Gatell | N. Clumeck | G. Fätkenheuer | P. Yeni | M. Peeters | P. Hay | M. Schöller-Gyüre | B. Woodfall | M. Simonts | M. Schöller‐Gyüre